Information Provided By: 
Fly News Breaks for April 29, 2016
ALKS
Apr 29, 2016 | 05:35 EDT
Barclays analyst Jonathan Eckard says Alkermes revenues are on a "solid path" for 2016 following the company's Q1 results. Focus will remain on the Aristada and Vivitrol launches, while updates around the depression drug ALKS-5461 could fuel investor interest, especially towards the end of the year, Eckard tells investors in a post-earnings research note. He continues to view continue Alkermes as a "solid stock" for 2016 and 2017 and keeps an Overweight rating on the name with a $50 price target.
News For ALKS From the Last 2 Days
There are no results for your query ALKS
